Biotech Translation and Policy

Map the R&D-to-clinic pathway for a set of advanced biotechnologies, including targeted nanomedicine for cancer and longevity therapies. Identify regulatory hurdles, clinical trial designs, patient access considerations, and economic models for equitable deployment. Propose governance mechanisms to balance safety with speed, and evaluate how partnerships among academia, industry, and public health agencies can accelerate translation without sacrificing ethics.